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Dietary patterns modulate the gut micro-
biota and alter its functions by modulat-
ing the production of GMMs, which are
capable of regulating homeostasis and
the risk of disease.
Complex interkingdom regulatory net-
works and crosstalk occur between the
host, its gut microbiota, and its diet.
Immortalized cancer cell lines grown in
2D monolayers differ genetically, meta-Dietary patterns, microbiome dysbiosis, and gut microbial metabolites (GMMs)
have a pivotal role in the homeostasis of intestinal epithelial cells and in disease
progression, such as that of colorectal cancer (CRC). Although GMMs and micro-
organisms have crucial roles in many biological activities, models for deciphering
diet–microbiome–host relationships are largely limited to animal models. Thus,
intestinal organoids (IOs) have provided unprecedented opportunities for the gen-
eration of in vitro platforms with the sufficient level of complexity to model physio-
logical and pathological diet–microbiome–host conditions. Overall, IO responses
to GMM metabolites and microorganisms can provide new insights into the
mechanisms by which those agents may prevent or trigger diseases, significantly
extending our knowledge of diet–microbiome–host interactions.bolically, and phenotypically from in vivo
cells. However, 3D IOs can mirror struc-
tural alterations, mutational signatures,
and gene expression changes between
patient and patient-derived organoids.
IOs provide new opportunities to study
how the gut microbiota , or its products,
interact with intestinal epithelial cells. In
this review, we discuss recent publica-
tions using IOs to study the nutrient–
microbiome axis in gastrointestinal ho-
meostasis and disease. We also highlight
an array of novel approaches by which
the nutrient–microbiota–gut epithelium tri-
angle can be further understood and
mechanisms governing gastrointestinal
diseases better deciphered.
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Are we really what we eat? Apart from its obvious nutritional value, food can also promote health and
prevent [1–6] or trigger [7,8] disease. Although diet exhibits a strong impact on health, complex inter-
relationshipswith thegutmicrobiota (seeGlossary), host genetics, and other environmental factors
are also needed for the propagation of disease [7]. After ingestion, food is digested into amultitude of
different small molecules in the gastrointestinal (GI) tract, some of which are absorbed by the intes-
tinal wall while others are further processed by the gut microbiome (Box 1). The gut microbiota com-
prises trillions of microorganisms that inhabit the humanGI tract, with low counts in the stomach and
proximal part of the small intestine compared with at least 1011 cells/g in the colon. These microor-
ganisms shape the chemical structure, lifespan, bioavailability, and biological activities of most of the
compounds ingested via diet, pharmaceuticals, and xenobiotics [9]. However, the relevance of die-
tary patterns, gut microbiota composition, and GMMs in tissue homeostasis and organ physiology
are poorly understood and we are only just beginning to understand the complex symbiosis be-
tween the gut and these microorganisms [7,10–15].
The European Prospective Investigation into Cancer and Nutrition (EPIC) study, one of the largest
cohort studies in the world, has established associations between fruit, vegetable, and fiber con-
sumption and a decreased risk of developing different forms of cancer [33]. High intake of dietary
phytochemicals, such as polyphenols, fiber, and antioxidant compounds, among others, have
been frequently associated with a reduced risk of GI cancers [2,7,34,35]. However, there are
unresolved questions regarding the mechanisms by which certain native phytochemical or
GMMs exert specific bioactivities.
To date, the most common approach to studying the effect of food components on intestinal
inflammation [36], toxicological interactions [37], microbiome research [38], or the potential bioac-
tivity of compounds, such as polyphenols against cancer [4,16,36,39], stems from the adminis-
tration of such native molecules to a variety of human 2D cell lines. However, such studies face
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Box 1. From Farm to Fork, and beyond
Diets rich in phytochemicals and fiber, commonly derived from several types of fruit and vegetable, have been associated
with a reduced risk of chronic diseases, such as cardiovascular and neurodegenerative diseases, obesity, diabetes, andGI
cancers [3,13,16–20]. However, the biological effects of these compounds cannot be directly linked to the native mole-
cules as they occur in the plant. Most nutrients are not metabolized in the oral cavity, and are resistant to the acidic con-
ditions in the stomach. For example, flavonoid glucosides are hydrolyzed in the brush border of the small intestine,
removing the attached sugar and releasing aglycone, which may then enter epithelial cells by passive diffusion as a result
of its increased lipophilicity and its proximity to the cellular membrane [21]. Before circulation into the blood stream,
aglycone reaches the liver, where it is conjugated, releasing sulfate, glucuronide, and methylated metabolites.
In most cases, phytochemicals, such as polymeric proanthocyanidins (PACs) reach the colon nearly intact [16,22], where,
together with nondigestible polysaccharides [23], they cross their destiny with the gut microbiota [22]. Here, polyphenols
and fiber undergo extensive microbial bioconversion (see Figure 1 in the main text), producing GMMs derived from poly-
phenols and short-chain fatty acids (SCFAs) [23,24]. GMMs can act either locally by exerting their bioactivity on intestinal
epithelial cells while concomitantly modulating the gut microbiota itself [9,20,22], or systemically, once absorbed, where
some are conjugated in the liver and then released in the bloodstream to target different organs, including the central ner-
vous system [25–27].
By contrast, a Western dietary pattern is characterized by high-sugar and high-fat foods, including highly processed foods
as a principal player. As a result, this dietary pattern can promote colonic inflammation and CRC [7,8]. For example, after
the consumption of a high-fat meal, bile acids are released into the duodenum, facilitating the emulsification and absorp-
tion of dietary lipids and fat-soluble vitamins. These cholesterol-derivedmetabolites are thenmetabolized in the intestine by
the gut microbiota, producing altered levels of secondary bile acids that may promote CRC [28,29]. Western dietary pat-
terns have been also linked to high levels of trimethylamine (TMA) and trimethylamine N-oxide (TMAO), microbiome-de-
rived metabolites produced by the metabolism of dietary carnitine and choline, and associated with CRC [30,31]. The
International Agency for Research on Cancer (IARC) concluded that processed meat was carcinogenic to humans on
the basis of sufficient evidence from studies of CRC [32]. Carcinogenic chemicals, such as N-nitroso-compounds
(NOC), polycyclic aromatic hydrocarbons (PAHs), and heterocyclic aromatic amines (HAA), may reach the colon and
cause increased levels of DNA adducts and DNA damage. The diet–gut microbiota–host triangle evolves as a promising
avenue in the prevention of GI diseases, such as CRC, but more research is required for a full understanding of gut homeo-
stasis, and disease prevention and propagation.
Trends in Endocrinology &Metabolismseveral classes of molecule cannot be directly linked to native compounds, but rather to their
metabolites [40–42]; and (ii) immortalized and cancer cell lines grown in 2D monolayers on plastic
minimally recapitulate key cellular complexities, topographies, and molecular signalling associ-
ated with 3D tissue architecture [38,43]. Although these observations are common to most bio-
active compounds and organ–diseases of interest, they are particularly relevant in GI diseases
given: (i) the precise cellular topography of the intestinal epithelium; (ii) the fact that dietary metab-
olites constantly influence intestinal epithelium; and (iii) the complex interaction among bacteria
and intestinal epithelial cells [17,22]. To overcome these issues, different animal models have
been utilized , offering a superior complexity over 2D models [27,44]. However, metabolic control
along with gut microbiota in these organisms is not the same as in humans [45,46], and human-
ized models do not necessarily reflect the real relationships seen in humans either. In the latter
case, the gut microbiota is transplanted into a host with which it has not coevolved, and
ecological factors, such as diet and disease genotype, that have initially driven the dysbiosis in
humans, are not present in rodent recipients [47].
Intestinal Organoid Cultures Reveal the Role of Phytochemicals in Tissue
Homeostasis and Diseases
Recently, protocols for establishing IOs have demonstrated that cells derived from adult tissue
biopsies and resection have the ability to survive, proliferate, and self-organize into 3D structures
in vitro (Box 2) that closely recapitulate the tissue of origin [48]. Thus, 3D IOs have proven to be
valuable model systems in studies aimed at not only deciphering normal tissue homeostasis, but
also investigating molecular mechanisms associated with disease onset, progression, and
response to therapy [49–54].Trends in Endocrinology & Metabolism, November 2020, Vol. 31, No. 11 849
Box 2. Establishment of Human Intestinal Organoids
Organoids can be derived from two fundamentally different sources: (i) using methods replicating human development, it is possible to derive IOs from pluripotent stem
cells (PSCs), including both embryonic stem cells and induced PSCs; and (ii) from tissuematerial, it is possible to extract organ-specific adult stem cells (ASCs) from both
normal and diseased tissues (Figure I). Both IO cultures can reflect the architecture, regional specification, and cell composition of the epithelium in vivo. On the one hand,
PSC-derived organoids are able to generate adjacent stromal cells and offer a more physiologically accurate model for studying the high complexity of mucosal inter-
actions. However, PSC-derived organoids do not necessarily reflect a specific regional identity. These 3D organoids recapitulate early stages of cellular proliferation and
are used for studying development processes and fetal infections. On the other hand, ASC-derived organoids may be better suited for modelling diseases since they are
genetically stable. Thus, ASC-derived organoids represent a promising system for studying the intestinal epithelium in homeostasis and disease. For example, ASCs can
be isolated from small clinical specimens from normal colon and CRC for establishing organoids that can be expanded to mimic the epithelial part of either the normal
colon or the cancer, respectively.
First, tissue resections and biopsies (Figure I) are kept in ice-cold phosphate buffered saline (PBS) until processing. Second, human crypts are then isolated, whereby
healthy and/or cancerous tissues are dissected into ~5-mm3 pieces and washed repeatedly with cold PBS. Subsequently, intestinal tissues are incubated in a chelation
solution supplemented with EDTA. After shaking, crypts, fragments of epithelium, or single cells are embedded in hydrogel. The hydrogel is a gelatinous protein mixture
derived from mouse tumour cells, and polymerizes rapidly at 22–35°C. The medium contains tissue-specific growth factors as described elsewhere [48,50,55]. Impor-
tantly, IO cultures preserve the in vivo cellular diversity [48], covering most, if not all, of the cellular lineages existing in the native intestinal tissue. Furthermore, identical
culture techniques can be applied to both normal tissue and neoplastic tissue and constitute a method for generating comprehensive panels of patient lines, thereby
embracing aspects of human genetic variation. However, important aspects to consider are that the work associated with deriving and maintaining panels of patient
line is labor intense and that, although IOs maintain the cellular complement of the epithelium, they lack immune cells, a functional nervous system, and a mesenchymal
niche.
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Figure I. Modelling Diet–Microbiome–Host Interactions in vitro. Schematic diagram summarizing the generation of intestinal organoids (IOs) from adult stem cells
(A) and pluripotent stem cells (PSCs) (B). On the one hand, intestinal crypts and singe cells separated from healthy and carcinogenic tissues are embedded in hydrogel
and the media containing growth factors is then added (A). On the other hand, PSC-derived IOs (B) can be differentiated following normal developmental stages to
generate intestinal epithelium. Afterwards, human IO and tumoroid responses to gut microbial metabolites (GMMs), such as short-chain fatty acids (SCFAs),
microbial catabolism of phytochemicals (CPs), secondary bile acids (BAs), trimethylamine N-oxide (TMAO), and trimethylamine (TMA), or microorganisms (MO) can
be evaluated by, among others, multi-omics approaches (see Box 3).
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vegetables come from the Brassica
genus, including broccoli, Brussels
sprouts, cabbage, cauliflower, collard
greens, kale, kohlrabi, mustard,
rutabaga, turnips, bok choy, and
Chinese cabbage. Brassicaceae (also
named Cruciferae) is a medium-sized
and economically important family of
flowering plants. They are mostly annual,
biennial, or perennial herbaceous plants
and, therefore, are available throughout
the year. Similar to other vegetables,
cruciferous vegetables contain a large
number of phytochemicals, including
folate, carotenoids, chlorophyll, as well
as fiber. However, cruciferous
vegetables are unique because they are
also rich sources of glucosinolates,
sulfur-containing compounds that are
responsible for their pungent aromas,
and spicy/bitter taste. Apart from
glucosinolates, cruciferous vegetables
are a rich source of nutrients produced
by the hydrolysis of glucosinolates, such
as indoles and isothiocyanates.
Fiber: parts of fruits and vegetables
containing substances such as
cellulose, lignin, and pectin-containing
carbohydrate polymers that are resistant
to endogenous digestive enzymes.
Dietary fiber can be considered a key
ancestral compound that preserves gut
ecology, regulating macronutrients and
host physiology.
Gut microbial metabolites (GMM):
humans rely on the microbiome to break
down dietary components, such as fiber
and phytochemicals, or release
metabolites, such as bile acids. GMMs
are bacterial fermentation products, and
these biochemical transformations
shape the chemical structures of such
compounds, thus modifying their
lifespan and bioavailability, and providing
different biological activities.
Gut microbiota: all microorganisms
found in the GI tract, including bacteria,
viruses, and fungi, with a fundamental
role in many host processes; it helps the
body to digest certain foods andwith the
production of vitamins or bioactive
metabolites. It also has a key role
combating infection, and supporting the
immune system.
Intestinal organoids (IOs): human or
mouse IOs are 3D in vitro tissue models
that incorporate several physiologically
relevant features of the in vivo gut
epithelium, such as a polarized epithelial
Trends in Endocrinology &MetabolismThe intestinal epithelium is a highly organized, self-renewing tissue with a proliferative crypt com-
partment and a differentiated villus [56]. The continuous cellular turnover of the intestinal epithe-
lium is conserved by stem cells at the bottom of the crypt, which generate transit-amplifying
cells, which then differentiate into various intestinal epithelial cells types, such as Paneth cells,
goblet cells, enteroendocrine cells, and enterocytes, among others. To evaluate the effect of
GMMs or microorganisms on gut health, an ideal model should preserve in vivo cellular diversity
and retain basic physiological functions of the intestinal epithelium.
In one benchmark study, Zietek and colleagues showed that organoids established from the small
intestine of mice preserved the main features of the intestinal epithelium in culture and could be
used for studying nutrient transport, nutrient sensing, and hormone secretion [57]. Consecutively,
human IOs were used to emulate nutrient transport physiology during digestion [58], and murine
IOs determined intestinal mechanisms for dietary fat absorption [59]. At this point, several groups
began studying various chemicals and dietary components that can promote or affect intestinal ep-
ithelium health. Cai and co-authors investigated the effects of different dietary constituents on IO
growth [60]. The authors observed that several dietary constituents did not significantly affect IO
growth. However, caffeic acid inhibited organoid growth in a concentration-dependent manner.
The higher the concentration of caffeic acid, the fewer crypt-like structures could be seen, and
these results were consistent with other in vitro research [61]. However, the results with other com-
pounds, such as monosodium glutamate and chlorogenic acid, were not in agreement with previ-
ous studies [60,62]. Thus, these results highlight that the use of organoids for testing
phytochemicals is still in its infancy. Future studies must carefully develop the experimental design
and consider not only that results may provide valuable insights related to in vivo models, rather
than in vitro 2D cell lines, but also that the observed responses are limited to the epithelial compo-
nent of the intestine.
Several observational studies have reported significant associations between a high intake of
cruciferous vegetables and lower risk of several types of GI cancer [63,64]. The potential health
benefits of consuming cruciferous vegetables are attributed to compounds such as indole-3-
carbinol (I3C), which was recently studied in small intestine mouse organoids [65]. The results pro-
vided robust evidence that I3C regulates Wnt and Notch signalling, with an important role in main-
taining normal cell fate and, in turn, goblet cell differentiation. However, the acidic environment of
the stomach can merge I3C molecules with each other to form a complex mixture of polycyclic ar-
omatic compounds, known as acid condensation products, such as 3,3'-diindolylmethane (DIM),
and the biological activities of such products may differ from those of I3C. By contrast, during the
transit of glucosinolates, formation of I3C may still occur, but to a lesser degree, in the large
intestine, due to themyrosinase activity of colonic bacteria [63,66]. Thus, the low, temporal amount
of I3C expected to reach the intestine could have a marginal impact on Wnt and Notch pathways.
This static and multicellular system may be an alternative strategy to animal models for the
prescreening of GMMs. Nevertheless, relevant findings must ultimately be validated in animals.
Besides the role of diet in the regulation of the intestinal epithelium homeostasis, organoids de-
rived from malignant colorectal lesions are opening new windows of opportunity to investigate
the impact of diet on tumorigenesis. Recently, Toden and colleagues reported a potent
chemoprotective role of flavan-3-ols (a commercial grape seed extract dissolved in DMSO, com-
prising monomers, dimers, and trimers) in CRC by studying IOs as a preclinical model system
[67]. Flavan-3-ols consistently suppressed the formation and growth of both IOs derived from
APCMin mouse and undeclared clinicopathological characteristics of human CRC tumoroids by
inhibiting the cell cycle and inducing programmed cell death. From a mechanistic point of view,
gene expression profiling revealed the suppression of prosurvival and self-renewal pathways,Trends in Endocrinology & Metabolism, November 2020, Vol. 31, No. 11 851
layer containing multiple cell types and a
functional lumen replicating real-life
conditions. IOs enable the study of gut
epithelial cells, investigating responses
to GMMs, microorganisms, or modelling
homeostasis and diseases. However,
IOs do not mimic the complexity of the
in vivo situation due to the lack of the
immune and nervous systems, and the
mesenchymal niche.
Phytochemicals: plant-derived
chemicals that occur in fruits,
vegetables, whole grains, nuts, seeds,
and legumes, being responsible for
color, taste, and smell, among other
characteristics.
Proanthocyanidins (PACs): present
in flowers, nuts, fruits, bark, and seeds of
various plants as a defense against biotic
and abiotic stressors; their astringency
protects the plant from pathogens and
predators. PACs are oligomeric and
polymeric products of the flavonoid
biosynthetic pathway. The building
blocks of PACs include the flavan-3-ols
catechin and epicatechin.
Trends in Endocrinology &Metabolismincluding Hippo signalling, in organoids treated with flavan-3-ols. Despite these promising
findings, from a nutritional point of view, proanthocyanidins (PACs) are subject to extensive
metabolism once introduced into the GI tract. These compounds can reach the distal GI tract
almost intact, where they are efficiently transformed into low-molecular-weight phenolic com-
pounds by the colonic microbiota [22,23,30,68,69]. Therefore, flavan-3-ol monomers, dimers,
and trimers reaching the colon become available to the gut microbiota. Then, microbial
catabolism begins, producing hydroxy-phenyl-γ-valerolactones (PVLs) and, to a lesser extent,
their derived hydroxy-phenylvaleric acids (PVAs), with only a small percentage of unmetabolized
PACs remaining [16,70]; for example, Choy and colleagues recovered only 11% of ingested
PACs in pig feces [71].
A formal demonstration of the influence of PAC catabolism in tumorigenesis was provided by
Ravindranathan and colleagues [72]. To test the potential benefit of combining PACs and
curcumin in the prevention of CRC, CRC cell lines were first treated with curcumin or PACs either
as single agents or in combination. The combined treatment of PACs and curcumin consistently
decreased the mRNA levels of the proliferation marker Cyclin D1, and the expression of PDE3B,
a gene associated with peroxisome proliferator-activated receptors (PPARs) and with inhibition
of proliferation and crosstalk between insulin signalling pathways. To strengthen their findings,
authors evaluated the combination of curcumin and PACs in vivo following the growth of subcu-
taneous xenografts of HCT116 cells in athymic mice. Interestingly, PACs efficiently decreased the
expression of both Cyclin D1 and PDE3B when administered as single agents. This suggest that
those responses were not likely to be modulated by PACs but rather by the release of GMMs,
which were shaped by the mouse microbial catabolism. However, the combination of curcumin
and PACs decreased the expression of Cyclin D1 and PDE3B and attenuated tumour growth
in vivo to a greater extent than curcumin or PACs administered as single agents. Lastly, the
authors established patient-derived tumoroids (stages IIA, IIB, and IIC) to confirm the trends
observed using 2D cell lines and mice models. The expression level of the genes encoding Cyclin
D1 and PDE3Bwas downregulated by the combination of curcumin and PACs. However, mRNA
levels of Cyclin D1 and PDE3B did not decrease when colon tumoroids were treated with native
PACs alone.
To date, most studies have investigated the role of phytochemicals on IOsmodelling homeostasis
and carcinogenesis. However, to the best of our knowledge, cancer initiation and propagation by
means of diet-related metabolites (Box 1) or the protective effects of GMMs in presence or
absence of carcinogenic agents have not yet been explored (see Outstanding Questions). Over-
all, IOs derived from either normal or diseased tissue provide a complementary mechanism for
studying the impact of dietary components on cell behaviour. Even though this technology repre-
sents an important tool for deciphering different pathological processes affecting humans and, in
turn, potentially allow us to identify mechanisms that can counteract diseases, experimental de-
signs should be readapted taking into account: (i) the digestion andmicrobial catabolism of native
dietary constituents to understand their metabolism and determine those compounds that reach
the gut epithelium; (ii) ideally, healthy and disease-related IO responses should be evaluated; and
(iii) the correct polarity of the gut should be considered for experiments with metabolites and di-
etary components to target either the apicobasal membrane for mimicking systemic exposure
or the apical membrane for luminal exposure (see later).
Investigating the Structural and Functional Changes Induced by the Microbiome
at the Gut Epithelium
Recent microbiome studies have expanded beyond simply profiling microbiota compositions, and
are increasingly characterizing microbial functions by using functional meta-omics approaches852 Trends in Endocrinology & Metabolism, November 2020, Vol. 31, No. 11
Trends in Endocrinology &Metabolism[73]. By combining meta-omics approaches, a functional profile can be obtained to the extent that
these techniques can provide strain-level taxonomic resolution, assess the potential functions
encoded, and quantify the metabolic activities occurring within a complex microbiome. As an ex-
ample, a shotgun metagenomic sequencing of bacterial DNA and metabolomics in cecal contents
in rats with type 2 diabetes mellitus (UCD-T2DM) supported the idea that diabetes-specific host
signals affect the ecology and GMMs of the gut microbiome when controlling for diet, age, and
housing environment [74]. The strength of analyzing both the activity and microorganisms is that
it revealed significant associations between the gut microbiome and human disease [11,31,73,75].
The gut epithelium is the principal site for detecting GMMs and microorganism, and both can act
locally (Figure 1) by exerting their bioactivity on intestinal epithelial cells. For example, fiber-derived
compounds, such as short-chain fatty acids (SCFAs), are fatty acids with saturated aliphatic tails
between two and six carbons long and have implications for both host health and disease
[8,69,76,77]. These GMMs have been commonly monitored in several biological fluids [24,78]. Al-
though the importance of studying these microbial and diet-related metabolites has increased
[77,79], their role in the human gut epithelium remains challenging to determine. Schilderink
and co-authors examined whether SCFAs induce the secretion of paracrine factors influencing
epithelial homeostasis [80]. Interestingly, butyric acid enhanced ALDH1A1 and ALDH1A3 expres-
sion in human and mouse IO cultures, respectively. The expression of ALDH1A1–3 is critical for
the epithelial conversion of retinol to retinoic acid. This work demonstrated the importance of
IOs in deciphering the physiological interaction between the gut epithelium and microbiome inTrends in Endocrinology & Metabolism
Figure 1. Linking Gut Microbial Metabolites (GMMs) with the Gut Microbiota and Diet. The digestion andmicrobia
catabolism of a diet rich in phytochemicals (PCs) and fiber (yellow boxes) produce short-chain fatty acids (SCFAs). By
contrast, a Western dietary pattern (red boxes) increases secondary bile acids (BAs) and levels of trimethylamine N-oxide
(TMAO) and trimethylamine (TMA), among others. This figure illustrates how food GMMs, with their metabolized forms
may act either locally on intestinal epithelial cells, concomitantly modulating the gut microbiota, or systemically once
absorbed through the gastrointestinal tract.
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Trends in Endocrinology &Metabolismhealthy conditions and identified a new mechanism by which butyrate, through induction of
retinoic acid synthesis, can contribute to maintain gut homeostasis. Serotonergic enterochromaffin
(EC) cells have been suggested to fulfil the role of chemosensors in the gut epithelium and, together
with tuft cells, they transduce chemosensory information to the nervous system [81–83].
Bellono and co-authors explored the applicability of IOs to decipher the role of certain GMMs
[82]. They demonstrated that EC cells express specific chemosensory receptors, are
electrically excitable, and modulate serotonin-sensitive primary afferent nerve fibers via synap-
tic connections, enabling them to detect and transduce environmental, metabolic, and homeo-
static information from the gut directly to the nervous system. Allyl isothiocyanate, isovalarate,
dopamine, epinephrine, and norepinephrine also specifically and consistently activated EC
cells. By contrast, SCFAs elicited small, but consistent responses to Ca2+ transients. In light
of these recent findings, IOs represent an excellent biological system to explore chemical
signals produced by the gut microbiota.
Exploring the influence of microorganisms on the intestinal epithelium is more complex than
studying the impact of metabolites. The gut epithelium is where microorganisms interact with
the host and, therefore, mirroring a real-life scenario means that microorganisms and, ideally,
complex mixtures of microorganisms have to be introduced into the lumen of the organoid.
However, this is technically challenging. Human and mouse IOs accurately mimic the gut
architecture, luminal accessibility, and tissue polarity [79], and three approaches have been
used so far for introducing microorganism into organoids: (i) disrupted organoids; (ii) 2D cultures
derived from IOs; and (iii) microinjections. For the first option, once organoids are disrupted, they
expose the apical side and, at this point, dissociated cells may interact with microorganism [84].
For example, a study jointly co-cultured IOs and lamina propria lymphocytes (LPLs) to explore the
protective effect of Lactobacillus reuteri D8 [85], which is considered a key player able to protect
the integrity of intestinal mucosa, although little is known regarding its effects on the stem cell
niche. The authors revealed that L. reuteri D8 promoted the growth of IOs, and protected
organoid morphology upon tumor necrosis factor alpha (TNF-α) treatment. Although elevated
levels of cells expressing Lgr5 were also observed, the antibody still needs to be validated
using tissue from knockout animals. The authors argued that L. reuteri D8 stimulates LPLs to
secret IL-22 through aryl hydrocarbon receptors (AhRs), which activates STAT3 phosphoryla-
tion to accelerate the regeneration of intestinal stem cells. To expose the apical part, another
option is to dissociate organoids into single cells and seed these cells onto an extracellular
matrix or coated dish, and then to add microorganisms directly into the culture media, allowing
interaction between the microorganisms and the host cell monolayer [86,87]. More recently, a
new technique has been developed that reverses IO polarity, whereby the apical surface everts
to face the media [88]. This emergent and effective model can probe barrier integrity, nutrient
uptake, and could open new possibilities for studying diet–microbiome–gut epithelium
interactions.
The approaches mentioned here have mainly been performed with aerobic bacteria; however,
most gut microbiota are anaerobic. To overcome the challenge of studying anaerobic microbiota
using IOs, which grow under normal oxygen concentrations, microinjection of microorganisms
into the lumen of IOs (estimated 10% O2) has been used [89]. In this study, the authors took
advantage of a high-throughput microinjection device, which facilitated efficient and reproducible
injections into the lumen of gut organoids. As well as this technological advance, this research
showed that, after fecal transplant, aerobic and anaerobic communities could be transferred
into the IO lumen and cultivated over 4 days, with little change in the relative composition of
microbial communities. The number of cells and size of organoids differ from one IO to the
other, and, thus the microbial cargo should be normalized taking into account dimensional854 Trends in Endocrinology & Metabolism, November 2020, Vol. 31, No. 11
Trends in Endocrinology &Metabolismparameters. This technical advance can open new horizons to investigate complex microbial
communities. Nevertheless, it will be important to align such studies with in vivo studies to ascer-
tain whether the observations truly recapitulate what happens inside the human gut.
Strategies to Evaluate Intestinal Organoid Responses to Microorganisms and
GMM Interactions: From Bulk Tissues to Single Cells
Cellular and molecular assessments have confirmed IO responses to GMMs and microorgan-
isms. However, to understand the mechanisms that underscore these interactions with, and
responses in, epithelial cells, a combination of multi-omics approaches is crucial (Box 3).
Omics approaches have traditionally been performed on biological fluids, homogenized tissues,
or homogenized cells, measuring the average gene expression, proteome, or metabolome
[6,90,91]. Focusing on small molecules, the exo- and intrametabolome of IOs can elucidate sig-
nificant metabolic processes affecting IOs and tumoroids, because metabolites represent both
the downstream output of the genome and the upstream input from the environment. However,
bulk omics approaches, such as proteomics and metabolomics, eliminate all spatial information,
morphology, and heterogeneity, which are vital to disentangle the essence of such complex
eukaryotic–prokaryotic networks. To overcome these limitations, mass spectrometry imaging
(MSI) has emerged as a novel potent tool to assess the heterogeneity of a tissue at a single cell
resolution [92–95]. Thus, by determining the spatial distribution and abundance of known or
unknown molecular species, MSI can identify the cellular distribution of specific GMMs in the IO
epithelium, the biotransformation of such compounds in metabolites, and the metabolic and/or
proteomic response of intestinal cells to the compound [96].
By performing ‘bulk’ ‘omics approaches, the variability in cell type composition can significantly
confound analyses of these data, since different biological processes continuously occur at the
single cell level and responses to chemical microenvironments may differ. Genomics, tran-
scriptomics, epigenomics, proteomics, and metabolomics are now increasingly focused on
the characterization of individual cells [97,98]. For example, single-cell RNA sequencing was
used to reveal adjustments in cell populations in IO cultured with different growth factors
[48], as well as the proportions of the different cell types and their responses to bacterial infec-
tions [99], such as Salmonella. However, such emergent techniques are expensive and tech-
nologically challenging, and MS approaches in particular may require a superior sensitivity,
and extended linear dynamic range and resolving power. However, they could clearly open
new horizons in the near future, enabling us to determine how GMMs and/or microorganismsBox 3. Multi-Omics Approaches
A multi-omics approach was recently used to obtain a holistic view of molecular mechanisms in mouse IOs cultured in
different defined mediums [100]. The research by Lindeboom and co-authors resulted in a novel workflow to investigate
metabolites and lipids of IOs and can be used to explain the potential of lipidomics and metabolomics approaches aim
at studying chemical signatures on IOs for diet-microbiome-host interactions. To isolate those compounds, the authors
used a two-phase extraction system that provided relevant biological signatures. As a result, lipidomics highlighted that
the metabolism of lipoproteins and lipids, such as glycerophospholipid biosynthesis and phospholipid metabolism, were
upregulated. In addition, metabolomics analysis revealed that amino acids were downregulated in stem cell-depleted IOs
and upregulated in stem cell-enriched IOs.
Thus, this study illustrated the potential of multi-omics approaches to provide valuable new insights into the differentiation
mechanisms. Extrapolating from this research to the topic of the current review, the combination of IOs and multi-omics
approaches, particularly comprehensive lipidomics and metabolomics, could provide new insights into the mechanisms
by which nutrient–gene or microbiome–gut epithelium interactions may influence the intestinal stem cell niche. This could
unlock new possibilities for understanding the role of GMMs and microorganisms in personalized nutrition as well as the
initiation, propagation, and prevention of GI diseases.
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Outstanding Questions
Dietary patterns are associated with
health outcomes, but there are
unresolved questions regarding the
mechanisms by which microorganisms
or GMMs may exert health benefits.
Can IOs provide support for the results
from epidemiological and dietary
observational studies and also provide
mechanistic insights?
The type, quantity, and biological activity
of GMMs produced in humans depend
on the composition of gut microbiota.
Can IOs reveal the mechanistic
responses to these subtle changes?
Can GMMs target the colonocyte
epigenome as a promising strategy for
reprogramming aberrant processes
associated with GI diseases, such as
CRC, at the early stages of the disease?
Subsequently, can GMMs be identified
and then associated with the native
phytochemicals and microorganisms
responsible for microbial catabolism?
Can the negative health effects driven
by GMMs, such as trimethylamine
(TMA), trimethylamine N-oxide (TMAO),
and secondary bile acids, be neutral-
ized by the positive effects of others,
such as SCFAs or polyphenol catabo-
lism? At the same time, can IOs reveal
these complex interactions?
IOs are continuously being improved.
However, can they be co-cultured to
include other cellular components that
are present in vivo, such as nerves,
immune cells, and muscles?
Trends in Endocrinology &Metabolismaffect the distribution of cell types, transcriptional factors, and the proteome and metabolome
in 3D IOs at the single cell level.
Concluding Remarks and Future Perspectives
New insights are rapidly being gained into the field of ‘nutrition and gut microbiota’. Several studies
have determined that, after the ingestion of phytochemicals and fiber, the gut microbiome starts a
complex microbiota catabolism that releases important GMMs. Overall, nutrients, GMMs, and the
microbial community maintain a healthy gut epithelium. By contrast, a Western dietary pattern pro-
motesmicroorganisms andGMMs that negatively affect the gut epithelium andmay accelerate dis-
eases. In most cases, studies have separately described the microorganisms present in the gut
community and proteins and/or metabolites in different biological fluids. Although recent multi-
omics approaches have revealed significant associations between the gut microbiome and
human GI diseases, the mechanisms by which GMM–gene interactions influence the stem cell
niche has received little attention thus far.
Recently, IO culture models have been demonstrated to be powerful tools to mirror the behaviour
of epithelial cells. On this basis, healthy IOs and tumoroids offer several particular advantages: (i) the
ability to investigate cell-type intrinsic mechanisms in normal and diseased tissue-derived
organoids; and (ii) the possibility to explore the expression, localization, and activity of proteins
and intracellular signalling processes led by several diet-related compounds, GMMs, and
microorganisms.
A proper experimental design, as described earlier, and the combination of IOs, GMMs, and
microorganisms will help answer unresolved questions related to the mechanisms by which
GMMs result in disease prevention and initiation, as well as microbiome–gut epithelium crosstalk.
We envision that the field might see many applications of IOs in the future; such approaches will
clarify the mechanisms responsible for diet–microbiome–host interactions, and will open new
possibilities for understanding, and treating, GI diseases.
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